News
-
-
-
-
COMMUNIQUÉ DE PRESSE
BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis
BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis. The designation provides key incentives for addressing drug resistance in TB treatment -
-
-
COMMUNIQUÉ DE PRESSE
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE
BioVersys and Shionogi enter global research collaboration for NTM clinical candidate. BioVersys grants Shionogi license option for leads from BV500 program -
-
-
